Chronic Lymphocytic Leukemia

A matching-adjusted indirect comparison showed favorable survival outcomes with zanubrutinib vs ibrutinib in treatment-naive chronic lymphocytic leukemia.

Tacabrutideg's safety profile was tolerable, and the drug had antitumor activity in BTK inhibitor–naive patients with CLL/SLL and other B-cell malignancies.

The first-in-class BTK degrader tacabrutideg produced an ORR of 94.1% at the recommended phase 2 dose in relapsed/refractory CLL/SLL.

Fixed-duration pirtobrutinib plus venetoclax and rituximab reduced the risk of progression or death by 45% in previously treated CLL.

Fixed-duration venetoclax/obinutuzumab more than doubled median PFS vs chlorambucil/obinutuzumab in previously untreated CLL.

Sonrotoclax plus zanubrutinib drove durable remissions across IGHV-mutated and del(17p)/TP53 CLL subgroups in an updated phase 1/1b analysis.

First-line zanubrutinib improved real-world treatment duration, time to next treatment, and survival in older chronic lymphocytic leukemia.

Atrial fibrillation was associated with real-world cardiovascular and health care resource utilization burden in CLL/SLL.

Suchitra Sundaram, MD, discusses the assortment of therapies available in chronic lymphocytic leukemia and frontline approaches.

Ibrutinib/Rituximab Preserves QOL vs FCR in Previously Untreated CLL

Ibrutinib monotherapy produced durable efficacy over 10 years in patients with or without TP53-mutated chronic lymphocytic leukemia.

Alexey Danilov, MD, PhD, and Tycel Phillips, MD, highlight key consensus viewpoints in lymphoma published from the 2025 Bridging the Gaps meeting.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Multipeptide vaccines in combination with BTK inhibitor–based regimens yielded safety and potent T-cell responses in chronic lymphocytic leukemia.

Pirtobrutinib plus venetoclax and rituximab improved PFS in relapsed/refractory CLL/SLL, meeting the primary end point of BRUIN CLL-322.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, chronic lymphocytic leukemia, salivary gland cancer, cholangiocarcinoma, and prostate cancer.

The final analysis of the phase 1/2 BRUIN trial showed consistent stability or improvements in PROs with pirtobrutinib in CLL/SLL and MCL.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, head and neck cancer, breast cancer, prostate cancer, and leukemia.

Jennifer R. Brown, MD, PhD, discusses the FDA approval of acalabrutinib plus venetoclax for chronic lymphocytic leukemia and how it improves QOL.

In a post hoc indirect comparison, data showed zanubrutinib was linked to improved PFS vs acalabrutinib/venetoclax in patients with treatment-naive CLL.

The top 5 OncLive TV videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, lung cancer, breast cancer, and prostate cancer.

Nicole Lamanna, MD, discusses both CLL 17 and FLAIR studies and their significance for chronic lymphocytic leukemia.

Nicole Lamanna, MD, discusses the implications of the FDA approval of frontline acalabrutinib plus venetoclax in CLL.

Nicole Lamanna, MD, discusses the FDA approval of first-line acalabrutinib plus venetoclax for CLL and the phase 3 AMPLIFY trial data that supported it.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in February 2026 spanning tumor types.